Core Viewpoint - Weigao Blood Purification's stock closed at 37.69 yuan, down 1.10%, with a rolling PE ratio of 33.88 times and a total market value of 15.505 billion yuan [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, positioning Weigao Blood Purification at 71st in the industry [1][2] - The company has a total of 59,754 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]
威高血净收盘下跌1.10%，滚动市盈率33.88倍，总市值155.05亿元